The safety and efficacy of Sabinsa's proprietary blend of non-animal sourced enzymes for people with dyspepsia are supported by results of a new randomized, double-blind, placebo-controlled study.

Data published in the Journal of Medicinal Food indicated that 60 days of supplementation with DigeZyme led to significant improvements in the severity of illness, dyspepsia and GI symptoms, while no such improvements were observed in the placebo group at the end of study.

The study also reported that the DigeZyme was safe and well-tolerated during the trial with no reported adverse events.

“We’re pleased to see additional research on our carefully designed digestive enzyme formula confirm health benefits that improve quality of life,” said Dr Muhammed Majeed, founder and chairman of the Sami-Sabinsa Group and lead author on the new paper. “Good digestion plays an important role in overall health and now we can clinically say that DigeZyme is part of that foundation...”